In The News
Yale School of Medicine – Dr. Roy S. Herbst honored at Friends of Cancer Research 25th Anniversary Dinner
The evening of May 10, 2022, the Friends of Cancer Research held their 25th Anniversary Dinner Celebration at the Four Seasons Hotel in Washington, DC.
OncLive – Superagonists Pull IL-15 Into Focus in Oncology Care
Following in the footsteps of the cytokine interleukin (IL)-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.1 Because
The ASCO Post – How to Get the Dose Right
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mirat
Oncology Times – Promises & Challenges of Multi-Cancer Early Detection Screening
Multi-cancer early detection screening tests from a sample of blood (liquid biopsy) can detect cancer signals at very early stages, leading to the hope of
Bloomberg Law – Lawmakers Seek to Boost FDA Power Over Fast-Tracked Drugs (1)
The FDA could remove from the market any drugs that obtained accelerated approval if they fail to show a clinical benefit under a proposed package
Pink Sheet – ctDNA Can Be Used For Patient Selection and Enrichment, But Not As Early Efficacy Endpoint, US FDA Says
Circulating tumor DNA (ctDNA) can be used as a biomarker in early-stage solid tumor clinical trials for purposes of patient selection, patient enrichment and as
BioCentury – FDA backs use of ctDNA in cancer drug development
FDA draft guidance issued Monday endorses ctDNA as a biomarker in drug development for early-stage, non-metastatic solid tumors, and lays out the agency’s thinking on
The Cancer Letter – Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing
Finding the MTD, or maximum tolerated dose, was a rarely challenged rule in trials of cytotoxic drugs. But drugs change—and ideologies change with them. Today,
Business Wire – ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is
The Hatchet – SMHS fourth-year addresses disparities in cancer treatment for HIV patients in new initiative
A new initiative from School of Medicine and Health Sciences fourth-year graduate student Allison Graeter is focusing on addressing disparities in cancer treatment for persons living with
